Clinical Trial Awareness: 5 Ongoing Clinical Trials Advancing Cervical Cancer Research
January is Cervical Cancer Awareness Month, a time to highlight a disease that continues to affect thousands of women each year despite being largely preventable, with new cases ranging from about 12,500 in 2021 to an estimated 13,360 in 2025. These numbers highlight the ongoing need for timely screening, HPV vaccination, and early detection, which together play a crucial role in reducing cervical cancer incidence and improving outcomes.
Alongside prevention and standard care, clinical research is also advancing how cervical cancer is detected, monitored, and treated. Clinical trials help focus not only on new therapies but also on improved screening methods, prevention strategies, and supportive care approaches. Finding and understanding these opportunities, however, can be challenging for patients and caregivers.
TrialX helps bridge this gap by connecting individuals with relevant, actively recruiting clinical trials based on their specific health conditions, making it easier to explore research options at different stages of care.
In this blog, we highlight five active and recruiting clinical trials for cervical cancer.
1. The eVOLVE-Cervical Study: Exploring Post-Treatment Care for High-Risk Cervical Cancer
Sponsor: AstraZeneca
What It’s Testing and Why It Matters
The eVOLVE-Cervical Study is examining whether an additional treatment called volrustomig may help manage high-risk, locally advanced cervical cancer after standard chemoradiation is completed. While chemoradiation is an effective first treatment, some individuals still face a higher risk of the cancer returning. This study is focused on understanding whether continued treatment after initial therapy can help reduce that risk.
Why It Stands Out
Rather than changing first-line treatment, this study looks at what comes next—an area where fewer clear options currently exist. It includes participants from many countries and healthcare settings, helping researchers understand how this approach performs across a broad population. The study also follows participants over time to track both disease outcomes and quality of life.
What It Could Mean for Patients
If successful, this study could:
- Provide evidence for an additional treatment option after chemoradiation
- Help lower the chance of disease progression or recurrence
- Inform future care plans for people with high-risk cervical cancer
Locations
This is a global study with recruiting sites across the United States, Canada, Europe, and other regions.
Learn more about the study and check your eligibility here.
2. RICE Technologies for Cervical Cancer Screening and Diagnosis
Sponsor: M.D. Anderson Cancer Center
What It’s Testing and Why It Matters
This study is evaluating several screening and diagnostic technologies designed to improve how cervical cancer and pre-cancerous changes are identified after an abnormal screening result. It compares a rapid point-of-care HPV lateral flow test with standard laboratory-based HPV testing (such as GeneXpert) and evaluates a multimodal optical imaging system, including mobile colposcopy and high-resolution microendoscopy, to assess cervical abnormalities. The accuracy of these tools is compared against biopsy results, which serve as the reference standard.
Why This Study Is Important
The study brings together technologies that aim to address common gaps in cervical cancer screening, particularly delays between testing, diagnosis, and follow-up care.
- Point-of-care HPV testing may provide results more quickly than lab-based tests.
- Self-collected HPV samples may help reach women who face barriers to clinic-based screening.
- Mobile imaging tools, including smartphone-based colposcopy, may allow cervical evaluation in settings without access to specialized equipment.
By evaluating these tools together, the study explores whether screening and diagnosis can be made more timely and accessible without reducing accuracy.
What It Could Mean for Patients
If these technologies are shown to be reliable, they could shorten the time between screening and diagnosis, reduce the need for multiple clinic visits, and support screening programs in community and low-resource settings.
Locations
The study is recruiting at clinical sites in Mozambique and at M.D. Anderson Cancer Center in the United States.
Click here to learn more about this clinical trial.
3. Sacituzumab Tirumotecan for Recurrent or Metastatic Cervical Cancer
Sponsor: Merck Sharp & Dohme LLC
What It’s Testing and Why It Matters
This Phase 3 clinical study is evaluating sacituzumab tirumotecan (MK-2870) as a second-line treatment for people with recurrent or metastatic cervical cancer whose disease has progressed after standard therapies, including platinum-based chemotherapy and immunotherapy. The study compares this investigational treatment with commonly used chemotherapy options chosen by the treating physician. Researchers are primarily looking at whether sacituzumab tirumotecan can help patients live longer, along with how the treatment affects disease progression and quality of life.
Sacituzumab tirumotecan is designed to deliver targeted treatment to cancer cells that express TROP2, a protein commonly found on cervical cancer cells, while limiting exposure to healthy tissue.
Why It Stands Out
Treatment options are often limited once cervical cancer becomes recurrent or metastatic. This study stands out because it is a large, global Phase 3 trial directly comparing a targeted therapy with existing second-line treatments. It also explores outcomes both in patients with high TROP2 expression and in the broader cervical cancer population, which may help clarify where this approach fits best in care pathways.
What It Could Mean for Patients
If the study proves effective, it could:
- Provide a new treatment option after standard therapies stop working
- Help define the role of targeted therapies in advanced cervical cancer
- Inform future treatment decisions based on tumor characteristics such as TROP2 expression
Locations
The study is recruiting across multiple countries, including sites in North America, Europe, Asia, and Latin America.
Learn more about the study and eligibility details here.
4. BMS-986340 Study: Evaluating a New Treatment Alone and in Combination for Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb
What It’s Testing and Why It Matters
This study is evaluating BMS-986340, an investigational treatment, in people with advanced or metastatic solid tumors that have progressed despite standard therapies. The study looks at BMS-986340 on its own and in combination with nivolumab (an immunotherapy) or docetaxel (a chemotherapy).
As a first-in-human study, the main focus is on understanding safety, how the drug is tolerated, and identifying appropriate dose levels. The study also collects early information on how tumors respond to treatment across multiple cancer types.
Why It Stands Out
This study includes a wide range of solid tumors, including cervical cancer, ovarian cancer, melanoma, lung cancer, colorectal cancer, pancreatic cancer, and triple-negative breast cancer. By testing the drug both alone and in combination with existing treatments, researchers can explore whether combining therapies may improve outcomes for patients whose cancers have limited treatment options.
What It Could Mean for Patients
If BMS-986340 shows acceptable safety and early signs of effectiveness, it could support further development of the drug in specific cancer types. The results may help guide future combination strategies and expand research options for patients with advanced cancers that have stopped responding to current treatments.
Locations
The study is recruiting at multiple locations across the United States, Canada, Europe, Asia, and Australia.
Click here to learn more about the study and eligibility criteria.
5. HPV Vaccine, Imiquimod, and Metformin Combination Trial (HPV-VIM)
Sponsor: Baylor College of Medicine
What It’s Testing and Why It Matters
This Phase 2 study is evaluating whether adding immune-boosting treatments to standard chemoradiation can improve outcomes for people with HPV-associated gynecologic cancers, including cervical, vaginal, and vulvar cancers.
The study combines an HPV vaccine, imiquimod (a topical immune-stimulating medication), and metformin (a commonly used metabolic drug) alongside standard cancer treatment. The goal is to strengthen the body’s immune response against HPV-driven tumors while patients receive radiation and chemotherapy.
Why It Stands Out
Most HPV vaccines are used to prevent cancer. This study is exploring whether an HPV vaccine can also play a role after cancer has already developed, when used directly in the tumor and paired with immune-activating medications.
By combining existing, widely used treatments in a new way, researchers are studying whether the immune system can be better activated to support standard therapy, without introducing an entirely new drug.
What It Could Mean for Patients
If this approach proves safe and effective, it could help improve disease control in locally advanced HPV-related gynecologic cancers. The findings may also guide research on combining immunotherapy with standard radiation and chemotherapy for HPV-driven cancers.
Locations
The study is recruiting in Texas, United States.
Learn more about study details here.
Why Awareness and Research Matter
Cervical cancer is the fourth most common cancer affecting women worldwide, yet it is also one of the most preventable. Ongoing clinical research continues to explore better ways to prevent, detect, and treat the disease. Staying aware of the latest clinical trials can help increase understanding of cervical cancer and support informed conversations around cervical health.
To learn more about ongoing clinical trials in cervical cancer, visit TrialX.com or sign up for the volunteer registry to receive updates about new research opportunities. You can also explore trusted resources such as the Cervical Cancer Foundation, the National Cervical Cancer Coalition, and TogetHer for Health to stay informed and engaged about cervical cancer.
